[go: up one dir, main page]

EP1451140A1 - Neues verfahren - Google Patents

Neues verfahren

Info

Publication number
EP1451140A1
EP1451140A1 EP02791150A EP02791150A EP1451140A1 EP 1451140 A1 EP1451140 A1 EP 1451140A1 EP 02791150 A EP02791150 A EP 02791150A EP 02791150 A EP02791150 A EP 02791150A EP 1451140 A1 EP1451140 A1 EP 1451140A1
Authority
EP
European Patent Office
Prior art keywords
naproxen
process according
compound
formula
nitrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02791150A
Other languages
English (en)
French (fr)
Inventor
Aldo Belli
Vincenzo Cannata
Telly Fonduca
Martin Hedberg
Andreas Westermark
Marco Villa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA, AstraZeneca AB filed Critical Nicox SA
Publication of EP1451140A1 publication Critical patent/EP1451140A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/02—Preparation of esters of nitric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/67—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/58—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment

Definitions

  • the present invention relates to a new process for the preparation of the 4-nitrooxybutyl ester of 2-(S)-(6-methoxy-2-naphtyl)-propanoic acid (herein after named (S)-naproxen) and to new intermediates prepared therein suitable for large scale manufacturing of (S)- naproxen.
  • the invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active compounds such as (S)-naproxen 4- nitrooxybutyl ester.
  • (S)-Naproxen 4-nitrooxybutyl ester is known for its pharmaceutical activity as an antiinflammatory and/or analgesic agent.
  • the advantages of (S)-naproxen 4-nitrooxybutyl ester compared to (SJ-naproxen are among others a good tolerance and the reduction of gastrointestinal side effects.
  • WO 01/10814 discloses a process for the preparation of (S)-naproxen 4-nitrooxyalkyl ester with an optical purity of 97%.
  • an acid halide of (Sj-naproxen is reacted with a nitrooxyalkanol in an inert organic solvent such as dichloromethane, chlorobenzene, xylene or toluene, to give a (S)-naproxen 4-nitrooxyalkyl ester.
  • an inert organic solvent such as dichloromethane, chlorobenzene, xylene or toluene
  • WO 95/09831 describes a process whereby the sodium salt of (SJ-naproxen is reacted with a halo-butanol such as 4-bromobutan-l-ol or 4-chlorobutan-l-ol. The ester is then halogenated in the presence of PBr 3 and the like. Alternatively, the monomeric ester is formed by reacting the sodium salt derivative with a 1,4-dihalobutane.
  • the monomeric ester with the terminal halogen is then reacted with a nitrate source such as silver nitrate.
  • a nitrate source such as silver nitrate.
  • the process may be performed in solvents such as chloroform, 1,4-dioxane, tetrahydrofuran and the like.
  • solvents such as chloroform, 1,4-dioxane, tetrahydrofuran and the like.
  • the process of the present invention uses a sulfonated intermediate.
  • This intermediate can be easily manufactured and is highly reactive for reactions with nitrate ions to form (S)- naproxen 4-nitrooxybutyl ester. Nitrate substitution of sulfonates has been described in the literature.
  • ES 2,073,995 discloses the syntheses of alkyl nitrate esters from alkylsulfonates or 4- toluenesulfonates and metal nitrates using solvents such as dimethyl formamide, dimethyl acetamide, acetonitrile or dimethylsulfoxide.
  • solvents such as dimethyl formamide, dimethyl acetamide, acetonitrile or dimethylsulfoxide.
  • dimethyl acetamide or dimethylsulfoxide as solvent in the synthesis of (S)-naproxen 4-(nitrooxy)butyl ester starting from for instance (SJ-naproxen 4-(methanesulfonyloxy)butyl ester gives a crude product which needs to be purified either by chromatography or by distillation to achieve a pharmaceutically acceptable quality.
  • the present invention provides for a new process to prepare (S)-naproxen 4-nitrooxybutyl ester. Further, it provides for a new process to prepare compounds, which are useful as intermediates in the preparation of pharmaceutically active compounds such as (S)- naproxen 4-nitrooxybutyl ester, especially with regard to large-scale manufacturing of said ester.
  • step 1 of the manufacturing process a compound of formula I
  • reaction step la is prepared in reaction step la or alternatively in a two step process of steps lb and lc.
  • step la ( ⁇ -naproxen, the acid halide or the salt derivative of (S)-naproxen
  • Rl is H or RSO 2 and R2 is RSO 2 and
  • R is C ⁇ -C 4 alkyl, C ⁇ -C alkylphenyl, phenyl, phenylmethyl, halophenyl, nitrophenyl, halogen, CF 3 or n-C 4 F 9 , and the halo is fluoro, chloro or bromo, to obtain the compound of formula I.
  • (S)-naproxen may first be converted to its corresponding acid halide as described in WO 01/10814.
  • the compound of formula I may be prepared in a two step process, whereby in step lb, a compound of formula III is obtained by reacting (S)-naproxen with the compound of formula II, whereby Rl and R2 are both H,
  • step lc wherein the compound of formula III may be reacted with RSO 2 Cl and
  • R is C ⁇ -C 4 alkyl, Cj-C 4 alkylphenyl, phenyl, phenylmethyl, halophenyl, nitrophenyl, halogen, CF 3 or n-C 4 F 9 , and the halo is fluoro, chloro or bromo, to give the compound of formula I.
  • the esterification step lb can be performed in a manner known to a person skilled in the art, for example by treating (S)-naproxen and the 1 ,4-butanediol (compound II) with an acidic or dehydrating agent selected from the group consisting of sulphuric acid or its salts, perchloric acid (e.g. 70%) or other suitable acids such as polystyrene sulphonic acids, zeolites, acidic clays, sand in combination with strong hydrophilic acids such as perchloric acid or gaseous hydrogen chloride and montmorillonites.
  • an acidic or dehydrating agent selected from the group consisting of sulphuric acid or its salts, perchloric acid (e.g. 70%) or other suitable acids such as polystyrene sulphonic acids, zeolites, acidic clays, sand in combination with strong hydrophilic acids such as perchloric acid or gaseous hydrogen chloride and montmorillonites.
  • the acids may be used in the gas, fluid or solid form.
  • the solid heterogeneous acids can relatively easily be filtered from the reaction solution and re-used in large-scale production processes.
  • Examples of other coupling reagents useful for the esterification step lb are carbodiimides such as N,N'-dicyclohexylcarbodiimide (DCC), acid chlorides such as oxalyl chloride, chloroformates such as isobutyl chloroformate or other reagents such as cyanuric chloride, NN '-carbon yldiimidazole, diethyl chlorophosphite, 2-chloro-l-methyl-pyridinium iodide and 2,2'-dipyridyl disulphide.
  • DCC N,N'-dicyclohexylcarbodiimide
  • acid chlorides such as oxalyl chloride
  • chloroformates such as isobutyl chloroformate
  • other reagents such as cyanuric chloride, NN '-carbon yldiimidazole, diethyl chlorophosphite
  • the reaction step lb may be performed in a solvent selected from the group consisting of aromatic hydrocarbons such as benzene or toluene, aliphatic hydrocarbons such as n- heptane, ketones such as methyl isobutylketone, ethers such as tetrahydrofuran or diethyleneglycol dimethyl ether, chlorinated hydrocarbons such as dichloromethane or chlorobenzene, or mixtures thereof.
  • aromatic hydrocarbons such as benzene or toluene
  • aliphatic hydrocarbons such as n- heptane
  • ketones such as methyl isobutylketone
  • ethers such as tetrahydrofuran or diethyleneglycol dimethyl ether
  • chlorinated hydrocarbons such as dichloromethane or chlorobenzene, or mixtures thereof.
  • Preferred solvents are non-polar and/or non acidic solvents.
  • an excess of 1 ,4-butanediol may be used as solvent optionally mixed with any of the other organic solvents mentioned above.
  • the total amount of solvents used in the esterification process step lb may vary between 0 to 100 volume parts per weight of starting material.
  • the temperature of the esterification step lb may be between -100°C to +130°C, preferably between 0°C and +120°C.
  • Step lb Compounds of formula III as obtained in step lb may be purified by way of a two-way extraction to obtain a solution comprising the compound of formula III having a chromatographic purity of at least 95% and prefarbly more than 97% (extraxtion step i) and a 1 ,4-butandiol content below about 0.2% (w/w) (extraction step ii).
  • extractive purification may be done batch-wise or continuously.
  • Extraction step i) In this reaction step the chromatographic purity is improved.
  • the solution used in this extraction step may comprise a mixture of i) 1,4-butanediol, ii) water and/or a low molecular weight aliphatic alcohol and iii) a hydrocarbon solvent or mixtures of organic solvents with hydrocarbon solvents.
  • the low molecular weight aliphatic alcohols may be selected from the group consisting of methanol, ethanol, propanol or mixtures thereof.
  • the hydrocarbon solvents may be selected from the group comprising of toluene, cumene, xylenes, ligroin, petroleum ether, halobenzenes, heptanes, hexanes, octanes, cyclohexanes, cycloheptanes and the like.
  • a suitable organic solvent may be selected from the groups consisting of ketones such as methyl iso-butyl ketone, ethers such as di-n-butyl ether, tert-huty ⁇ methyl ether and aliphatic esters such as ethyl acetate and «-butyl acetate, haloalkanes like dichloromethane or mixtures thereof.
  • ketones such as methyl iso-butyl ketone
  • ethers such as di-n-butyl ether, tert-huty ⁇ methyl ether
  • aliphatic esters such as ethyl acetate and «-butyl acetate
  • haloalkanes like dichloromethane or mixtures thereof haloalkanes like dichloromethane or mixtures thereof.
  • the extraction is performed to lower the 1 ,4-butanediol-content and performed after extraction step i) wherein the chromatographic purity is improved as described above.
  • the solution may comprise i) a mixture of water and/or a low molecular weight aliphatic alcohol and ii) an organic solvent or mixtures of organic solvents.
  • the low molecular weight aliphatic alcohols may be selected from the group consisting of methanol, ethanol, propanol, or mixtures thereof.
  • a suitable organic solvent may be selected from the groups consisting of aromatic hydrocarbons such as toluene, cumene, xylenes, ketones such as methyl iso-bvtiyX ketone, ethers such as di-n-butyl ether, tert-butyl methyl ether and aliphatic esters such as ethyl acetate and n-butyl acetate, haloalkanes like dichloromethane or mixtures thereof.
  • the purified compound of formula III having a chromatographic purity of at least 95% and preferably at least 97% and a 1 ,4-butanediol content below about 0.2% (w/w) is obtained as a solution in the organic solvent system and may then optionally be isolated by removal of the volatile solvents by vacuum distillation.
  • reaction condition in step lc would suitably involve an excess of RSO 2 Cl in an organic solvent or a mixture of organic solvents.
  • a suitable solvent in step lc may be selected from the groups consisting of aromatic hydrocarbons such as toluene, cumene, xylenes, ketones such as methyl w ⁇ -butyl ketone, ethers such as di-n-butyl ether, tert-butyl methyl ether and tetrahydrofuran, aliphatic nitriles such as acetonitrile and aliphatic esters such as ethyl acetate and rc-butyl acetate, haloalkanes like dichloromethane, or mixtures thereof.
  • aromatic hydrocarbons such as toluene, cumene, xylenes
  • ketones such as methyl w ⁇ -butyl ketone
  • ethers such as di-n-butyl ether, tert-butyl methyl ether and tetrahydrofuran
  • aliphatic nitriles such as acetonitrile
  • Preferred solvents in step lc are toluene, xylenes, ethyl acetate, acetonitrile, butyl acetate and isopropyl acetate.
  • a base may be added in step lc.
  • the base may be selected from the group consisting of triethylamine, pyridine, N-methylmorpholine, diisopropylethylamine, tributylamine and N- methyl-piperidine.
  • the preferred bases are triethylamine and N-methylmorpholine.
  • a catalyst such as 4-(dimethylamino)pyridine may be used in step lc.
  • step lc may be purified by crystallisation from an organic solvent, optionally using a hydrocarbon as antisolvent to obtain a crystalline solid having a purity of about 95% and preferably about 97% and an optical purity equal or better than the (S)-naproxen used as starting material for step lb.
  • Suitable solvents used for the crystallisation may be selected from the group consisting of aromatic hydrocarbons such as toluene, cumene, xylenes, ketones such as methyl iso-butyl ketone, ethers such as di-n-butyl ether, tert-butyl methyl ether and tetrahydrofuran, aliphatic nitriles such as acetonitrile and aliphatic esters such as ethyl acetate and butyl acetate, or mixtures thereof.
  • aromatic hydrocarbons such as toluene, cumene, xylenes
  • ketones such as methyl iso-butyl ketone
  • ethers such as di-n-butyl ether, tert-butyl methyl ether and tetrahydrofuran
  • aliphatic nitriles such as acetonitrile
  • aliphatic esters such as ethyl acetate
  • Preferred solvents in step lc are toluene, xylenes, ethyl acetate, acetonitrile, butyl acetate and isopropyl acetate.
  • a suitable antisolvent for the crystallisation may be used toluene, cumene, xylenes, ligroin, petroleum ether, halobenzenes, heptanes, hexanes, octanes, cyclohexanes, cycloheptanes and the like.
  • step 2 of the manufacturing process (S)-naproxen 4-nitrooxybutyl ester (formula IV)
  • nitrate source selected from the group consisting of lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zink nitrate or tetraalkylammonium nitrate (wherein alkyl is a Ci-Cjs-alkyl, which may be straight or branched).
  • Preferred nitrate sources may be selected from the group consisting of lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate and calcium nitrate.
  • a suitable organic solvent in step 2 is preferably a polar aprotic solvents which may be selected from the group consisting of N-methylpyrrolidinone, /V. ⁇ -dimethylacetamide, sulpholane, tetramethylurea or l,3-dimethyl-2-imidazolidinone or nitriles such as acetonitrile, or mixtures thereof.
  • a polar aprotic solvents which may be selected from the group consisting of N-methylpyrrolidinone, /V. ⁇ -dimethylacetamide, sulpholane, tetramethylurea or l,3-dimethyl-2-imidazolidinone or nitriles such as acetonitrile, or mixtures thereof.
  • solvents may be aromatic hydrocarbons such as toluene, aliphatic hydrocarbons such as n-heptane, ketones such as methyl ethyl ketone, methyl isobutylketone, ethers such as tetrahydrofuran or diethyleneglycol dimethyl ether, chlorinated hydrocarbons such as chlorobenzene, aliphatic esters such as ethyl acetate, butyl acetate or isopropyl acetate, nitrated hydrocarbons such as nitromethane, ethylene glycols such as polyethylene glycol and mixtures of these, optionally with an added aliphatic alcohols such as methanol, ethanol, n-propanol, i-propanol, n-butanol, i-butanol or t-butanol.
  • aromatic hydrocarbons such as toluene
  • aliphatic hydrocarbons such as n-heptane
  • the nitration step 2 may also be performed in water, optionally in combination with any of the above listed organic solvents.
  • the nitration step 2 may optionally be performed with a phase-transfer-catalyst.
  • a phase transfer-catalyst may be used tetraalkylammonium salt, arylalkylammonium salt, tetraalkylphosphonium salt, arylalkylphosphonium salt, crown ether or ethylene glycol such as pentaethylene glycol, hexaethylene glycol or polyethylene glycol, or mixtures thereof.
  • a detergent may be used in the nitration step 2 to enhance the solubility of the starting material.
  • a detergent may be used any commercially available non-ionic or ionic surfactant alone or in combinations.
  • a non-ionic surfactant may be selected from the group consisting of sugar esters such as sorbitan monolaurate, sorbitan monooleate and polymeric surfactants such as polyoxyethylene sorbitan monostearate.
  • An ionic surfactant may be selected from the group consisting of glycolic acid ethoxylate alkyl ether, alkali metal alkyl 3-sulfopropyl ethers, sodium lauryl sulfate, sodium laureth sulfate, disodium laureth sulfonsuccinate, sodium stearate and cetyltrimethylammonium halides.
  • the nitration step 2 may be performed in water, optionally in combination with any of the above listed organic solvents and/or phase-transfer-catalysts and/or detergents.
  • the purity of the end product obtained in step 2 is preferably at least about 97%, particularly preferred at least about 98% and the optical purity is preferably similar or superior than the optical purity of the (S)-naproxen starting material.
  • C ⁇ -C 4 alkyl means an alkyl having 1 to 4 carbon atoms and includes both straight and branched chain alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.
  • C ⁇ -C alkylphenyl means mefhylphenyl, ethylphenyl n-propylphenyl, i- propylphenyl, n-butylphenyl, i-butylphenyl and t-butylphenyl.
  • phenylmethyl means benzyl
  • halo and halogen refer to fluoro, chloro or bromo.
  • halophenyl and "nitrophenyl” refer to phenyl groups substituted with one or more halogen or nitro group.
  • large scale means a manufacturing scale in the range of "kilogram to multiton".
  • the temperature used in process step 1 and 2 may be between -100°C to +130°C.
  • the temperature is preferably kept below 130 °C, because the stability of the end product might be affected by a high temperature. Particular preferred is a temperature between room temperature and 120°C. Room temperature shall mean a temperature between 18°C and 25°C.
  • Reaction step 2 is preferably performed at a temperature below 90°C.
  • the total amount of solvents may vary between 0 to 100 volume parts per weight of starting material.
  • Another advantage of the process of the present invention is that the enantiomeric purity of the starting material is at least maintained in the end product.
  • a further object of the present invention is the compound of formula I
  • R is phenylmethyl, halophenyl, nitrophenyl, halogen, CF 3 or n-C 4 F and the halo is fluoro, chloro or bromo
  • Another object of the present invention relates to the use of the compound of formula I, wherein R is Cj-C 4 alkyl, phenyl, phenylmethyl, C ⁇ -C alkylphenyl, halophenyl, nitrophenyl, halogen, CF 3 or n-C 4 F , and the halo is fluoro, chloro or bromo, as an intermediate for the manufacturing of a pharmaceutically active compound.
  • Yet another object of the present invention relates to the use of the compound of formula I, wherein R is C ⁇ -C 4 alkyl, phenyl, phenylmethyl, C ⁇ -C 4 alkylphenyl, halophenyl, nitrophenyl, halogen, CF 3 or n-C 4 F 9 and the halo is fluoro, chloro or bromo, as an intermediate for the manufacturing of (S)-naproxen 4-nitrooxybutyl ester.
  • Yet another object of the present invention is the use of (S)-naproxen 4-nitrooxybutyl ester prepared according to the process described above under step 1 and 2, for the manufacturing of a medicament for the treatment of pain.
  • (S)-Naproxen 4-hydroxybutyl ester A mixture of (S)-naproxen (15.57 g, 67.6 mmol), 1,4- butanediol (76.5 g, 850 mmol), sodium hydrogen sulfate monohydrate (0.97 g, 7.0 mmol) and toluene (35 ml) was heated to 80 °C for 17 h. After cooling to room temperature the mixture was extracted with 5 % aqueous sodium chloride (75 ml) and 10% aqueous sodium bicarbonate (60 ml). The organic layer was then dried over anhydrous sodium sulfate, filtered and evaporated to dryness to give 15.0 g of red oil.
  • (S)-Naproxen (5.0 kg, 21.7 mol) was mixed with 1 ,4-butanediol (19.6 kg, 217 mol) and the stirred mixture was heated to 80°C.
  • Sulfuric acid (42.5 g, 433 mmol) was added and the resulting reaction mixture was stirred at 80°C for 6.5 h.
  • the aqueous layer was separated from the organic layer.
  • Toluene (2.5 kg) and hexanes (2.5 kg) were added to the aqueous layer at 50°C and the resulting two-phase system was stirred for 15 min before phase separation. This latter extraction of the aqueous layer was repeated twice using the same amounts of toluene (2.5 kg) and hexanes (2.5 kg). Toluene (13.0 kg) and 0.2 M potassium carbonate (aq) (14.9 kg) were added to the aqueous layer at 50°C and the resulting two-phase system was stirred for 25 min before phase separation. Water (14.9 kg) was added to the organic layer at 50°C and the resulting two-phase system was stirred for 15 min before phase separation.
  • (S)-Naproxen 4-hydroxybutyl ester procedure using purification by extraction.
  • (S)-Naproxen 200 g, 0.869 mol
  • 1 ,4-butanediol 783 g, 8.69 mol
  • Sulfuric acid 4.0 g, 40 mmol
  • the second 1 ,4-butanediol-layer was added to the aqueous layer and the combined aqueous layer was extracted with a mixture of toluene (1 10 ml) and hexanes (156 ml) at 50°C. After phase separation the organic layer was extracted twice with 1 ,4-butanediol (2 x 50 ml) at 50°C and the 1,4-butanediol-layer were added to the aqueous layer. The combined aqueous layer was extracted between toluene (700 ml) and 0.2 M potassium carbonate (aq) (800 ml) at 50°C with stirring for 10 min before phase separation.
  • (S)-Naproxen 4-(4-toluenesulfonyloxy)butyl ester using purification by chromatography.
  • (S)-Naproxen 4-hydroxybutyl ester (7.33 g, 24.2 mmol) was mixed with toluene (40 ml) under stirring at room temperature.
  • 4-toluenesulfonyl chloride (6.01 g, 31.5 mmol)
  • 4-(dimethylamino)pyridine (0.30 g, 2.4 mmol
  • triethylamine 6.7 ml, 48.5 mmol
  • the resulting mixture was heated at 40°C bath temperature for 7 h after which more 4-toluenesulfonyl chloride (0.92 g, 4.8 mmol) was added. The reaction was then continued for another 18 h at 40°C bath temperature. After allowing the mixture to cool to room temperature, 10% aqueous hydrochloric acid (30 ml) was added under stirring. Stirring was continued for about 15 min when the two phases were separated and the toluene-layer was extracted with 10% aqueous sodium bicarbonate. The toluene-layer was then dried over anhydrous sodium sulfate, filtered and evaporated to dryness to give yellow oil.
  • (S)-Naproxen 4-(methanesulfonyloxy)butyl ester using purification by crystallisation.
  • methanesulfonyl chloride (3.68 g, 32.1 mmol) and toluene (40 ml) were charged to a three-necked round bottomed flask. The mixture was stirred and to the resultant clear solution was added triethylamine (3.07 g, 30.3 mmol), drop-wise from the dropping funnel the temperature increasing to 60°C during the addition.
  • N- Methylmorpholine (2.1 kg, 20.8 mol) was added over 54 min with efficient stirring during which the inner temperature increased from 38.5°C to 45.8°C.
  • the addition vessel was rinsed with toluene (3.1 kg divided in two portions) letting the washing phase to go into the reaction mixture.
  • the reaction mixture was then stirred for 4 h at 43°C before raising the temperature to 58°C.
  • 0.1 M sulfuric acid (22.4 kg) was added and the resulting two-phase system was stirred at 58°C for 22 min before phase separation.
  • the organic layer was mixed with water (22.4 kg) and the resulting two- phase system was stirred at 58°C for 16 min before phase separation and the temperature of the organic layer was then raised to 61 °C.
  • the obtained crystals were recrystallized according to the same procedure using toluene (31 kg) and after washing the filtered crystals with toluene (9.7 kg) at 20°C and drying under vacuum at 36°C for 20 h 5.0 kg (71%) of pure (S)-naproxen 4-(methanesulfonyl-oxy)butyl ester having a chromatographic purity of 99.5%, an assay of 97.6% (w/w) and an optical purity of 99.8% enantiomeric excess was obtained.
  • (S)-Naproxen 4-(methanesulfonyloxy)butyl ester using purification by crystallisation.
  • (S)-Naproxen 4-hydroxybutyl ester (200 g, 0.661 mol) and toluene (1.40 L) were mixed and the resulting solution was stirred and heated to 40°C.
  • Methanesulfonyl chloride (85.0 g, 22.7 mol) was added and the mixture was stirred for 20 min at 40°C.
  • N- Methylmorpholine (71.7 g, 0.709 mol) was added over 10 min with efficient stirring.
  • the reaction mixture was then stirred for 3 h 15 min at 40°C before another portion of N- methylmorpholine (6.8 g, 0.067 mol) was added. After stirring for another 60 min at 40°C another portion of N-methylmorpholine (3.3 g, 0.033 mol) was added and the reaction was allowed to continue for another 80 min (total reaction time 4 h 35 min). The reaction was then complete according to LC and 0.1 M sulfuric acid (700 ml) was added. The resulting two-phase system was stirred at 40°C for 15 min before phase separation.
  • the organic layer was mixed with water (700 ml) and the resulting two-phase system was stirred during heating to 60°C for 40 min before another portion of toluene (100 ml) and water (200 ml) was added. Stirring at 60°C was continued for another 15 min before phase separation.
  • the volume of the organic layer was then reduced by vacuum distillation at a jacket temperature of 60°C so that approximately half of the toluene (about 600 ml) remained, n- Heptane (800 ml) was added and after cooling from an inner temperature of 53°C to 4°C over 2 h a slurry was obtained which was filtered.
  • (S)-Naproxen 4-(4-chlorobenzenesulfonyloxy)butyl ester (S)-Naproxen 4-hydroxybutyl ester (10.0 g, 33.1 mmol) was mixed with acetonitrile (40 ml) and the resulting solution was cooled down to 5°C under stirring. 4-Chlorobenzenesulfonyl chloride (10.4 g, 49.1 mmol) was added and to the resulting solution at 5°C N-methylmorpholine (4.3 ml, 39.1 mmol) was added with efficient stirring. A white precipitate gradually formed and the reaction mixture was stirred over night at 5°C after which LC showed 91% conversion.
  • Example 10 using purification by chromatography.
  • the obtained oil was then partitioned between toluene (20 + 10 ml) and water (20 ml) and after phase separation the organic layer was dried using sodium sulfate, filtered and evaporated to dryness to give 2.64 g of an orange oil.
  • the first aqueous layer above was reextracted with toluene (30 + 10 ml) and this second toluene layer was also dried using sodium sulfate, filtered and evaporated to dryness to give 0.47 g of a less viscous orange oil.
  • Example 11 using purification by chromatography.
  • (S)-Naproxen 4-nitrooxybutyl ester was prepared essentially according to Example 4 above but starting from (S)-naproxen (4-methanesulfonyloxybutyl) ester (8.33 g, 21.9 mmol), sodium nitrate (3.72 g, 43.8 mmol) and N-methylpyrrolidinone ( ⁇ MP, 23 ml).
  • the reaction temperature used was 80 °C and the reaction time 21 h. After work up using extraction between toluene and water 7.30 g of crude product was obtained. This was purified by column chromatography on silica gel eluting with heptane/ethyl acetate (4: 1).
  • Example 13 large scale Example.
  • the organic layer was washed with water (6.6 kg) for 17 min before phase separation and this extraction was repeated using water (6.6 kg) to give an organic layer containing less than 0.1% (w/w) of ⁇ MP after phase separation.
  • the organic layer was filtered to remove any solids and after vacuum distillation to dryness at a jacket temperature of between 40°C and 46°C, 1.04 kg (73%) of (S)-naproxen 4-(nitrooxy)butyl ester was obtained as a yellow oil.
  • the chromatographic purity was 98.6%, the assay 98.6% (w/w), the water content ⁇ 0.1% (w/w), the tert-butylmethyl ether content 0.3% (w/w), the ⁇ MP content 0.1% (w/w) and the butandiol content 0.1% (w/w).
  • the optical purity as determined using LC was 99.8% enantiomeric excess.
  • the organic layer was washed with water (8.0 kg) for 15 min before phase separation and this extraction was repeated using water (8.0 kg), to give an organic layer containing less than 0.1% (w/w) of NMP after phase separation.
  • the organic layer was filtered to remove any solids and after vacuum distillation to dryness at a jacket temperature of between 43 °C and 1.43 kg (77%) of (S)-naproxen 4-(nitrooxy)butyl ester was obtained as a yellow oil.
  • the chromatographic purity was 98.4%, the assay 97.8% (w/w), the water content 0.1% (w/w), the tert-butylmethyl ether content 0.3% (w/w), the NMP content 0.2% (w/w) and the butandiol content 0.1% (w/w).
  • the optical purity as determined using LC was 99.8% enantiomeric excess.
  • Example 15 A mixture of (S)-naproxen 4-(methanesulfonyloxy)butyl ester (3.03 g, 7.96 mmol), lithium nitrate (1.70 g, 24.7 mmol) in sulpholane (12 ml) was heated under stirring at 83°C for 31 h when LC showed >99.5% conversion. The reaction mixture was allowed to cool down to room temperature before it was partitioned between water (24 ml) and tert-butyl methyl ether (24 ml). The organic phase was washed with water (24 ml) and evaporated to dryness under vacuum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EP02791150A 2001-11-27 2002-11-26 Neues verfahren Withdrawn EP1451140A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103978 2001-11-27
SE0103978 2001-11-27
PCT/SE2002/002184 WO2003045896A1 (en) 2001-11-27 2002-11-26 New process

Publications (1)

Publication Number Publication Date
EP1451140A1 true EP1451140A1 (de) 2004-09-01

Family

ID=20286124

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02791150A Withdrawn EP1451140A1 (de) 2001-11-27 2002-11-26 Neues verfahren

Country Status (6)

Country Link
US (2) US20050234123A1 (de)
EP (1) EP1451140A1 (de)
JP (1) JP4771659B2 (de)
AU (1) AU2002365372A1 (de)
CA (1) CA2465697C (de)
WO (1) WO2003045896A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321420A (zh) * 2020-11-03 2021-02-05 浙江海翔川南药业有限公司 一种萘普生杂质及其制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
ITMI20021861A1 (it) * 2002-08-29 2004-02-29 Nicox Sa Procedimento di sintesi di nitrossialchilesteri di acidi carbossilici, intermedi impiegabili in detto procedimento e loro preparazione.
RU2259348C1 (ru) * 2004-02-04 2005-08-27 ФГУП "Бийский олеумный завод" Способ получения 2-этилгексилнитрата непрерывным методом
CN101903328B (zh) * 2007-12-20 2013-05-15 Dsm精细化学奥地利Nfg两合公司 利用湍流模式下的连续产物萃取在微反应器和毫反应器中形成硝酸酯
ITRM20080325A1 (it) * 2008-06-20 2009-12-21 Nicox Sa Metodo per purificare 4-(nitroosi)butil(2s)-2-(6-metossi-2-naftil) propanoato
JP5580625B2 (ja) 2010-03-03 2014-08-27 住友化学株式会社 メタンスルホン酸アルキルエステル溶液の製造方法
TWI417276B (zh) 2011-03-01 2013-12-01 Everlight Chem Ind Corp ２-（ｓ）-（６-甲氧基-２-萘基）-丙酸之酸酐衍生物、其製法暨及其用途
WO2025184555A1 (en) * 2024-02-28 2025-09-04 Northrop Grumman Systems Corporation Methods of producing a nitrate ester

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2073995B1 (es) * 1993-05-17 1996-03-01 Espanola Explosivos Procedimiento para la obtencion de nitratoalquil oxetanos.
DK0722434T3 (da) * 1993-10-06 1998-11-16 Nicox Sa Salpetersyreestere, der har anti-inflammatorisk og/eller analgetisk aktivitet og fremgangsmåder til deres fremstilling
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
IT1313596B1 (it) * 1999-08-04 2002-09-09 Nicox Sa Processo per la preparazione di nitrossialchil esteri del naproxene
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6355666B1 (en) * 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03045896A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321420A (zh) * 2020-11-03 2021-02-05 浙江海翔川南药业有限公司 一种萘普生杂质及其制备方法

Also Published As

Publication number Publication date
JP4771659B2 (ja) 2011-09-14
CA2465697A1 (en) 2003-06-05
CA2465697C (en) 2010-05-11
JP2005510557A (ja) 2005-04-21
US20050234123A1 (en) 2005-10-20
US20110034719A1 (en) 2011-02-10
WO2003045896A1 (en) 2003-06-05
AU2002365372A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
US20110034719A1 (en) Process for the preparation of (s)- naproxen 4-nitrooxybutyl ester
JP2001518459A (ja) 葉酸拮抗剤を作成するのに有用な方法及び中間体
US6262262B1 (en) Processes and intermediates useful to make antifolates
JP2005510557A6 (ja) 新規な方法
JP4528123B2 (ja) ナプロキセンのニトロオキシ誘導体の製造法
EP0905128B1 (de) Verfahren und Zwischenprodukte, die für die Herstellung von Antifolaten verwendbar sind
WO2004026808A1 (en) Manufacturing process for no-donating compounds such as no-donating diclofenac
EP0274194B1 (de) Verfahren zur Herstellung von 2-Nitro-5-phenoxy-N-alkylsulfonylbenzamiden durch Nitrierung
CN111548257B (zh) 一种（4-异丙氧基-2-甲基）苯基异丙基酮的制备方法
EP1246796B1 (de) Verfahren zur herstellung von diphenylether-verbindung
JP3868534B2 (ja) スルホンアミド誘導体の製造法および中間体
JP2003500465A (ja) アルコキシケイ皮酸エステルの製造方法
JP4038657B2 (ja) アダマンタノンの製造方法
ITMI20011772A1 (it) Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
US5516934A (en) Process for producing mono-P-nitrobenzyl malonate
JP2002501940A (ja) 高純度の混合無水（メタ）アクリル酸の製造方法
JPH04273887A (ja) モノハロアルカノイルフェロセンの合成方法
JP3613657B2 (ja) 光学活性Ｎ置換α−アミノ−γ−ハロゲノ酪酸エステルの製造方法
JP2006527186A (ja) 分割することのない３−アリール−２−アルコキシ・プロパン酸の調製方法
TW202130617A (zh) 製備１，１’－二硫烷二基雙（４－氟－２－甲基－５－硝基苯）之方法
JPH03227974A (ja) キノリン―８―スルホン酸の製造方法
JP2005112810A (ja) ベンジル（ジフルオロメチル）スルフィド化合物の製造方法
ZA200502224B (en) Manufacturing process for no-donating compounds such as no-donating diclofenac.
HK1020437B (en) Processes and intermediates useful to make antifolates
KR20000010402A (ko) 2-[(2,6-디클로로페닐)아미노]페닐아세톡시아세트산의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20040727

R17P Request for examination filed (corrected)

Effective date: 20040628

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NICOX SA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NICOX S.A.

17Q First examination report despatched

Effective date: 20090827

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 203/04 20060101ALI20120127BHEP

Ipc: C07C 309/73 20060101ALI20120127BHEP

Ipc: C07C 309/67 20060101ALI20120127BHEP

Ipc: C07C 309/66 20060101ALI20120127BHEP

Ipc: C07C 303/28 20060101ALI20120127BHEP

Ipc: C07C 201/02 20060101ALI20120127BHEP

Ipc: C07C 67/58 20060101ALI20120127BHEP

Ipc: C07C 69/734 20060101ALI20120127BHEP

Ipc: C07C 67/08 20060101AFI20120127BHEP

RTI1 Title (correction)

Free format text: PROCESS FOR THE PREPARATION OF (S)-NAPROXEN 4-NITROOXYBUTYL ESTER

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CANNATA, VINCENZO

Inventor name: VILLA, MARCO

Inventor name: FONDUCA, TELLY

Inventor name: HEDBERG, MARTIN

Inventor name: BELLI, ALDO

Inventor name: WESTERMARK, ANDREAS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120601